ASCO 2019: 40-50 percent response rate for brigatinib after other next-gen ALK inhibitors

IMAGE: D. Ross Camidge, MD, PhD and the ATOMIC consortium show that brigatinib remains effective even after first-line therapy with another next-generation ALK inhibitor. view more  Credit: University of Colorado Cancer Center Crizotinib was the first drug licensed to treat ALK-positive non-small cell lung cancer (ALK+ NSCLC). Since then, a range of next-generation ALK-inhibitors including ceritinib,…

Cancer-fighting combination targets glioblastoma

Chestnut Hill, Mass. (5/30/2019) – Researchers have paired a specialized diet and a tumor-fighting drug and found the non-toxic combination helps to destroy the two major cells found in an aggressive form of brain cancer, the team reports in the online edition of the Nature group journal Communications Biology. The international team combined a calorie-restricted…